Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.

about

Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.

P2860

Q26775512-E74CF5CD-DCE6-444B-9477-3C08D8279A84 Q48054105-0DD5C725-3E5F-48CB-B2B2-AD3200FC20EB

P2860

Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.

Item

http://www.wikidata.org/entity/Q38130348

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Impact of the European paediat ...... ogy: past, present and future.

@en

type

Item

label

Impact of the European paediat ...... ogy: past, present and future.

@en

prefLabel

Impact of the European paediat ...... ogy: past, present and future.

@en

P1476

Impact of the European paediat ...... ogy: past, present and future.

@en

P2093

Agnes Saint-Raymond

http://www.w3.org/2001/XMLSchema#string

Alberto Martini

http://www.w3.org/2001/XMLSchema#string

Paediatric Rheumatology International Trials Organisation (PRINTO)

http://www.w3.org/2001/XMLSchema#string

Richard Vesely

http://www.w3.org/2001/XMLSchema#string

P2860

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.

Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis.

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement

Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs.

The safety profile of biologic therapies for juvenile idiopathic arthritis.

Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO).

P304

1893-1896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2013-204168

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicolino Ruperto

P577

2013-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23962457

http://www.w3.org/2001/XMLSchema#string

Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.

about

P2860

P2860

Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698